{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:19:21Z","timestamp":1793089161554,"version":"4.5.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Department of Rheumatology of the Erasmus MC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We systematically reviewed the literature to identify the incidence of PsA flare, criteria used to define it and associated risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Databases of Embase, Medline ALL, Web of Science Core Collection and Cochrane Central Register of Controlled Trials were searched until September 2023, for original articles studying PsA flare. The Newcastle\u2013Ottawa scale was used to assess the quality of included studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-four studies of cohort, cross-sectional and clinical trial designs were included. Twelve studies assessed PsA flare rates, 28 assessed risk factors and 44 defined flare. The prevalence of current flare ranged between 7% and 50% (n\u2009=\u20098), while the incidence ranged between 10% and 27% over 6\u2009months (n\u2009=\u20093), and 22% and 23% over 12\u2009months (n\u2009=\u20092). Based on high-quality scoring, the current patient-reported flare was 10% (n\u2009=\u20091), while current physician-reported flare was 7% with 22\u201323% incidence rate over 12\u2009months (n\u2009=\u20092). Criteria used in flare definition could be grouped into seven categories, with disease activity scores (36%), patient-reported (39%) and physician-reported (30%) flare and change in therapy (25%) being frequently used. Risk factors could be grouped into four categories: arthritis therapies, SARS-CoV, PsA features and other. The factors showed limited or unclear evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The current prevalence of flare ranged between 7% and 10%, and the annual incidence was 22\u201323%, based on high-quality scoring. Forty-four studies defined flare, revealing no consensus on a single flare definition, and highlighting the need for a standardized definition. No conclusions could be drawn on risk factors, highlighting the need for further research.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration<\/jats:title>\n                  <jats:p>CRD42024482657<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf247","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:50:46Z","timestamp":1747738246000},"page":"4886-4901","source":"Crossref","is-referenced-by-count":7,"title":["Psoriatic arthritis flare incidence, definition and risk factors: a systematic review"],"prefix":"10.1093","volume":"64","author":[{"given":"Batoul","family":"Hojeij","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonul Hazal","family":"Koc","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda J","family":"Luime","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, University of Oxford , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-6926","authenticated-orcid":false,"given":"Marc R","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-8330","authenticated-orcid":false,"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Albert Schweitzer Hospital , Dordrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2025090315125049700_keaf247-B1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090315125049700_keaf247-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025090315125049700_keaf247-B3","doi-asserted-by":"crossref","first-page":"105511","DOI":"10.1016\/j.jbspin.2022.105511","article-title":"Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries","volume":"90","author":"Sousa","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025090315125049700_keaf247-B4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3899\/jrheum.211302","article-title":"Impact of physician-defined flares on quality of life and work impairment: an international survey of 2238 patients with psoriatic arthritis","volume":"50","author":"Orbai","year":"2023","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B5","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125049700_keaf247-B6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/rheumatology\/kex503","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"57","author":"Edwards","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125049700_keaf247-B7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3899\/jrheum.161347","article-title":"Utility of power doppler ultrasound-detected synovitis for the prediction of short-term flare in psoriatic patients with arthritis in clinical remission","volume":"44","author":"Ruta","year":"2017","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B8","author":"Alvaro-Gracia","year":"2023"},{"key":"2025090315125049700_keaf247-B9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-030-19412-3_3","volume-title":"Creating healthy and sustainable buildings: an assessment of health risk factors","author":"Dovjak","year":"2019"},{"key":"2025090315125049700_keaf247-B10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s42358-023-00316-0","article-title":"Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study","volume":"63","author":"Fong","year":"2023","journal-title":"Adv Rheumatol"},{"key":"2025090315125049700_keaf247-B11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Declaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025090315125049700_keaf247-B12","author":"Wells","year":"2024"},{"key":"2025090315125049700_keaf247-B13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00296-017-3862-7","article-title":"Psoriatic arthritis quality of life questionnaire: translation, cultural adaptation and validation into Portuguese language","volume":"38","author":"Barcelos","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025090315125049700_keaf247-B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s42358-021-00168-6","article-title":"Psoriatic arthritis quality of life questionnaire: translation, cultural adaptation and validation into Brazilian Portuguese language","volume":"61","author":"Goncalves","year":"2021","journal-title":"Adv Rheumatol"},{"key":"2025090315125049700_keaf247-B15","doi-asserted-by":"crossref","first-page":"e55912","DOI":"10.1371\/journal.pone.0055912","article-title":"Validity and reliability of the Dutch adaptation of the psoriatic arthritis quality of life (PsAQoL) questionnaire","volume":"8","author":"Wink","year":"2013","journal-title":"PLoS ONE"},{"key":"2025090315125049700_keaf247-B16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009740903347975","article-title":"Adaptation of the psoriatic arthritis quality of life (PsAQoL) instrument for Sweden","volume":"39","author":"Billing","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2025090315125049700_keaf247-B17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3899\/jrheum.201317","article-title":"Evaluation and validation of a patient-completed psoriatic arthritis flare questionnaire","volume":"48","author":"Helliwell","year":"2021","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B18","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/kev009","article-title":"It\u2019s not just the joints, it\u2019s the whole thing: qualitative analysis of patients\u2019 experience of flare in psoriatic arthritis","volume":"54","author":"Moverley","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125049700_keaf247-B19","first-page":"193","article-title":"Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis","volume":"37","author":"Scriffignano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090315125049700_keaf247-B20","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumat"},{"key":"2025090315125049700_keaf247-B21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"2025090315125049700_keaf247-B22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial","volume":"285","author":"Goll","year":"2019","journal-title":"J Intern Med"},{"key":"2025090315125049700_keaf247-B23","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s10067-021-05728-1","article-title":"High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry","volume":"40","author":"Fornaro","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025090315125049700_keaf247-B24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"2025090315125049700_keaf247-B25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/09546634.2019.1606886","article-title":"Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study","volume":"31","author":"Bonifati","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2025090315125049700_keaf247-B26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/art.41716","article-title":"Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090315125049700_keaf247-B27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10067-015-2886-1","article-title":"A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))","volume":"34","author":"Moverley","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090315125049700_keaf247-B28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.12688\/hrbopenres.13274.1","article-title":"Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis","volume":"4","author":"Marzaioli","year":"2021","journal-title":"HRB Open Res"},{"key":"2025090315125049700_keaf247-B29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3899\/jrheum.171152","article-title":"Maternal and fetal outcomes in a cohort of patients exposed to tumor necrosis factor inhibitors throughout pregnancy","volume":"45","author":"Genest","year":"2018","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jdv.12997","article-title":"The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures","volume":"30","author":"Bakkour","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090315125049700_keaf247-B31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2020-218705","article-title":"Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort","volume":"80","author":"Ciurea","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090315125049700_keaf247-B32","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","article-title":"Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials","volume":"4","author":"Skaria","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090315125049700_keaf247-B33","doi-asserted-by":"crossref","first-page":"SI143","DOI":"10.1093\/rheumatology\/keac249","article-title":"Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"61","author":"Rider","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125049700_keaf247-B34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","article-title":"Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine","volume":"24","author":"Spinelli","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090315125049700_keaf247-B35","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090315125049700_keaf247-B37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","article-title":"Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey","volume":"7","author":"Tillett","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090315125049700_keaf247-B38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.semarthrit.2017.01.002","article-title":"Psoriatic arthritis disease activity during pregnancy and the first-year postpartum","volume":"46","author":"Polachek","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090315125049700_keaf247-B39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-018-4385-7","article-title":"Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls","volume":"38","author":"Polachek","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090315125049700_keaf247-B40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/annrheumdis-2011-201208","article-title":"Does the change in season affect disease activity in patients with psoriatic arthritis?","volume":"71","author":"Touma","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025090315125049700_keaf247-B41","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheum"},{"key":"2025090315125049700_keaf247-B42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jbspin.2014.11.002","article-title":"Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS)","volume":"82","author":"Cozzi","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2025090315125049700_keaf247-B43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/RHU.0000000000001863","article-title":"A safety analysis of programmed death 1 pathway inhibitors in patients with solid tumor malignancies and preexisting autoimmune disease","volume":"28","author":"Higgins","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025090315125049700_keaf247-B44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.knee.2022.12.017","article-title":"Postoperative flares and peri-arthroscopic management of immunosuppressive medications in patients with rheumatic disease","volume":"41","author":"Vasavada","year":"2023","journal-title":"Knee"},{"key":"2025090315125049700_keaf247-B45","first-page":"613","article-title":"Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study","volume":"41","author":"Scrivo","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025090315125049700_keaf247-B46","doi-asserted-by":"crossref","first-page":"102959","DOI":"10.1016\/j.jaut.2022.102959","article-title":"Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)","volume":"134","author":"Ma","year":"2023","journal-title":"J Autoimmun"},{"key":"2025090315125049700_keaf247-B47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/vaccines11020476","article-title":"Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: results of 1-year prospective follow-up study","volume":"11","author":"Gazitt","year":"2023","journal-title":"Vaccines"},{"key":"2025090315125049700_keaf247-B48","first-page":"667","article-title":"Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs","volume":"41","author":"De Stefano","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025090315125049700_keaf247-B49","doi-asserted-by":"crossref","first-page":"1207015","DOI":"10.3389\/fimmu.2023.1207015","article-title":"The impact of SARS-CoV-2 infection and vaccination on inflammatory arthritis: a cohort study","volume":"14","author":"Striani","year":"2023","journal-title":"Front Immunol"},{"key":"2025090315125049700_keaf247-B50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/acr.24837","article-title":"Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease","volume":"74","author":"Dharia","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090315125049700_keaf247-B51","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00404-022-06463-x","article-title":"Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare","volume":"306","author":"Allen","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"2025090315125049700_keaf247-B52","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1097\/RHU.0000000000001790","article-title":"A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease","volume":"28","author":"Gupta","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025090315125049700_keaf247-B53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7196\/SAMJ.2021.v111i8.15795","article-title":"Access to chloroquine in patients with rheumatic and musculoskeletal diseases attending rheumatology outpatient clinics during the COVID-19 pandemic","volume":"111","author":"Ntshalintshali","year":"2021","journal-title":"S Afr Med J"},{"key":"2025090315125049700_keaf247-B54","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090315125049700_keaf247-B55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinthera.2017.03.005","article-title":"Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons","volume":"39","author":"Wolf","year":"2017","journal-title":"Clin Ther"},{"key":"2025090315125049700_keaf247-B56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2334-13-278","article-title":"CD64 as a potential biomarker in septic arthritis","volume":"13","author":"Oppegaard","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2025090315125049700_keaf247-B57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00296-022-05119-y","article-title":"Safety of SARS-CoV-2 vaccination in patients with Behcet\u2019s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine","volume":"42","author":"Ozdede","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025090315125049700_keaf247-B58","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/03009742.2023.2164979","article-title":"Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial","volume":"52","author":"Uhrenholt","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"2025090315125049700_keaf247-B59","first-page":"25","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomized controlled non-inferiority trial","volume":"8","author":"Michielsens","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2025090315125049700_keaf247-B60","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40744-021-00345-5","article-title":"Cost-effectiveness of therapeutic drug monitoring-guided adalimumab therapy in rheumatic diseases: a prospective, pragmatic trial","volume":"8","author":"Gomez-Arango","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090315125049700_keaf247-B61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semarthrit.2007.03.004","article-title":"A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis","volume":"37","author":"Kivitz","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"2025090315125049700_keaf247-B62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/JMDH.S104807","article-title":"Information bias in health research: definition, pitfalls, and adjustment methods","volume":"9","author":"Althubaiti","year":"2016","journal-title":"J Multidiscip Health"},{"key":"2025090315125049700_keaf247-B63","doi-asserted-by":"crossref","first-page":"852220","DOI":"10.3389\/fmed.2022.852220","article-title":"Insights into the concept of rheumatoid arthritis flare","volume":"9","author":"Bozzalla-Cassione","year":"2022","journal-title":"Front Med-Lausanne"},{"key":"2025090315125049700_keaf247-B64","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3899\/jrheum.161107","article-title":"Defining flare in osteoarthritis of the hip and knee: a systematic literature review\u2014OMERACT virtual special interest group","volume":"44","author":"Cross","year":"2017","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B65","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","article-title":"Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090315125049700_keaf247-B66","doi-asserted-by":"crossref","first-page":"110576","DOI":"10.1016\/j.pnpbp.2022.110576","article-title":"Age-associated alterations in immune function and inflammation","volume":"118","author":"Lewis","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2025090315125049700_keaf247-B67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/cimm.2000.1623","article-title":"Seasonal variations in cytokine expression and cell-mediated immunity in male rhesus monkeys","volume":"200","author":"Mann","year":"2000","journal-title":"Cell Immunol"},{"key":"2025090315125049700_keaf247-B68","doi-asserted-by":"crossref","first-page":"e37230","DOI":"10.1097\/MD.0000000000037230","article-title":"The relationship between disease activity with pan-immune-inflammatory value and systemic immune-inflammation index in rheumatoid arthritis","volume":"103","author":"Ba\u015faran","year":"2024","journal-title":"Medicine"},{"key":"2025090315125049700_keaf247-B69","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2025090315125049700_keaf247-B70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1017\/S0029665112000092","article-title":"Obesity, inflammation and the immune system","volume":"71","author":"de Heredia","year":"2012","journal-title":"Proc Nutr Soc"},{"key":"2025090315125049700_keaf247-B71","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"key":"2025090315125049700_keaf247-B72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11926-013-0323-5","article-title":"Synovium and the innate inflammatory network in osteoarthritis progression","volume":"15","author":"Liu-Bryan","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025090315125049700_keaf247-B73","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","article-title":"Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis","volume":"61","author":"Uhrenholt","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125049700_keaf247-B74","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3899\/jrheum.160193","article-title":"Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis","volume":"43","author":"Han","year":"2016","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2025090315125049700_keaf247-B76","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.170153","article-title":"GRAPPA 2016 project report","volume":"44","author":"Helliwell","year":"2017","journal-title":"J Rheumatol"},{"key":"2025090315125049700_keaf247-B77","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1093\/rheumatology\/keab220","article-title":"What influences patients\u2019 opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology"},{"key":"2025090315125049700_keaf247-B78","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3899\/jrheum.160118","article-title":"Development of a flare instrument for use in psoriatic disease: a report from the 2015 GRAPPA annual meeting","volume":"43","author":"Moverley","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf247\/63244286\/keaf247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4886\/63244286\/keaf247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4886\/63244286\/keaf247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:12Z","timestamp":1756926792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/4886\/8138391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":78,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,20]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf247","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,20]]}}}